Quoting Aman Chauhan, Leader of the Sylvester Comprehensive Cancer Center’s Neuroendocrine Tumor Program, on Twitter:
“Congratulations to Crinetics Pharmaceuticals team on a very positive results for paltusotine phase 3 acromegaly study!! We are now even more excited for Paltusotine Carcinoid study. Please checkout our Trials in Progress Poster from ENETS.”
For details click here.
Source: Aman Chauhan/Twitter